Form 4: LifeMD Chairman and CEO Justin Schreiber Sells 25,000 Shares Under Pre-Arranged Plan

LifeMD, Inc. Chairman and CEO Justin Schreiber reported the sale of 25,000 shares of common stock for approximately $311,655, executed under a Rule 10b5-1 trading plan.

Summary

• Justin Schreiber, Chairman and CEO, Director, and 10% Owner of LifeMD, Inc. (LFMD), reported a direct sale of common stock.
• The transaction involved 25,000 shares of common stock disposed of directly by Mr. Schreiber.
• The sale occurred on June 2, 2025, and was made pursuant to a Rule 10b5-1(c) trading plan.
• The weighted average sale price for the shares was $12.4662, with individual transactions ranging from $11.9750 to $12.9200.
• The total value of the shares sold is approximately $311,655 (25,000 shares * $12.4662/share).
• Following this transaction, Mr. Schreiber directly beneficially owns 200,000 shares of Common Stock.
• Indirect beneficial ownership includes 2,525,721 shares held by Schreiber Holdings LLC, 13,997 shares by Child 1, and 13,997 shares by Child 2.

Sentiment

Score: 4

Explanation: A score of 4 reflects a slightly negative sentiment due to the insider sale by the Chairman and CEO, despite it being under a 10b5-1 plan. While pre-scheduled, it still represents a reduction in direct ownership by a key insider.

Positives

• The sale was conducted under a Rule 10b5-1 trading plan, indicating it was pre-scheduled and not a reaction to immediate negative news, which can mitigate negative market perception compared to unscheduled sales.

Negatives

• A significant insider sale by the Chairman and CEO, even if pre-planned, reduces direct ownership and can be perceived negatively by the market, potentially signaling a lack of confidence or a desire for diversification.

Risks

• Potential negative market perception and investor sentiment due to the insider sale by a key executive.

Future Outlook

The document does not provide any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This Form 4 filing is a routine disclosure of an insider stock transaction and does not provide broader industry context or trends. It reflects an individual executive's portfolio management rather than a company-wide strategic move.

Stakeholder Impact

• Shareholders may interpret the insider sale as a negative signal, potentially impacting investor confidence and the stock price.

Next Steps

• The document does not mention any specific future actions, events, or milestones for the company.

Key Dates

Recommendation

Keywords

LifeMD, LFMD, Justin Schreiber, Insider Sale, Form 4, SEC Filing, Stock Transaction, CEO, Chairman, 10b5-1 Plan